iCAD, Inc.

How big is iCAD, Inc.?

As of Jun 18, iCAD, Inc. has a market capitalization of 104.27 million and reported net sales of 19.53 million with a net profit of -5.22 million for the latest four quarters. Shareholder's funds are 28.68 million, and total assets amount to 37.54 million.

As of Jun 18, iCAD, Inc. has a market capitalization of 104.27 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 19.53 million for the latest four quarters, while the net profit for the same period was -5.22 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 28.68 million and total assets amounting to 37.54 million.

What does iCAD, Inc. do?

iCAD, Inc. specializes in advanced image analysis, workflow solutions, and radiation therapy for cancer detection and treatment, with a market cap of USD 104.27 million. As of March 2025, it reported net sales of USD 5 million and a net profit loss of USD 1 million.

Overview:<BR>iCAD, Inc. is a provider of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer, operating in the Pharmaceuticals & Biotechnology industry with a market cap of USD 104.27 Million.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 104.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.64 <BR>Return on Equity: -16.98% <BR>Price to Book: 3.39<BR><BR>Contact Details:<BR>Address: 98 Spit Brook Rd Ste 100, NASHUA NH: 03062-5737 <BR>Tel: ['1 603 8825200', '61 917 7491494'] <BR>Fax: 1 603 8803843 <BR>Website: http://www.icadmed.com

Should I buy, sell or hold iCAD, Inc.?

Who are in the management team of iCAD, Inc.?

As of March 2022, the management team of iCAD, Inc. includes Mr. Michael Klein as Executive Chairman and CEO, along with independent directors Mr. Nathaniel Dalton, Dr. Rakesh Patel, Mr. Andrew Sassine, and Dr. Susan Wood.

As of March 2022, the management team of iCAD, Inc. includes Mr. Michael Klein, who serves as the Executive Chairman of the Board and Chief Executive Officer. Additionally, the board consists of independent directors: Mr. Nathaniel Dalton, Dr. Rakesh Patel, Mr. Andrew Sassine, and Dr. Susan Wood.

Is iCAD, Inc. technically bullish or bearish?

As of July 10, 2025, iCAD, Inc. shows a bullish technical trend with strong daily moving averages and Bollinger Bands, despite mixed signals from the MACD and Dow Theory, while significantly outperforming the S&P 500 year-to-date and over the past year.

As of 10 July 2025, the technical trend for iCAD, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands indicate a bullish stance. However, the MACD shows a mildly bearish signal on the weekly timeframe, while the monthly MACD is bullish. The KST is bullish on both weekly and monthly timeframes, but Dow Theory indicates a bearish trend on the monthly level. <BR><BR>In terms of performance, iCAD has significantly outperformed the S&P 500 year-to-date with a return of 111.48% compared to 12.22%, and over the past year, it has returned 184.56% against the S&P 500's 17.14%. Overall, the current technical stance is bullish, albeit with some mixed signals in the indicators.